Search

Charles E. Cooley

Examiner (ID: 18400, Phone: (571)272-1139 , Office: P/1774 )

Most Active Art Unit
1774
Art Unit(s)
1797, 1774, 1723, 2402, 1754, 3405
Total Applications
4063
Issued Applications
3143
Pending Applications
300
Abandoned Applications
659

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 14213969 [patent_doc_number] => 20190119369 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-25 [patent_title] => METHOD OF TREATING OR PREVENTING LIVER CONDITIONS [patent_app_type] => utility [patent_app_number] => 16/095021 [patent_app_country] => US [patent_app_date] => 2017-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24778 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16095021 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/095021
METHOD OF TREATING OR PREVENTING LIVER CONDITIONS Apr 20, 2017 Abandoned
Array ( [id] => 14309665 [patent_doc_number] => 20190144536 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => ASPROSIN, A FAST-INDUCED GLUCOGENIC PROTEIN HORMONE [patent_app_type] => utility [patent_app_number] => 16/092653 [patent_app_country] => US [patent_app_date] => 2017-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44216 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16092653 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/092653
ASPROSIN, A FAST-INDUCED GLUCOGENIC PROTEIN HORMONE Apr 12, 2017 Abandoned
Array ( [id] => 17274456 [patent_doc_number] => 20210380654 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => HUMAN FIBROBLAST GROWTH FACTOR 21 (HFGF21) FUSION PROTEIN, PREPARATION METHOD THEREFOR, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/604088 [patent_app_country] => US [patent_app_date] => 2017-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11283 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16604088 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/604088
HUMAN FIBROBLAST GROWTH FACTOR 21 (HFGF21) FUSION PROTEIN, PREPARATION METHOD THEREFOR, AND USE THEREOF Apr 9, 2017 Pending
Array ( [id] => 11949494 [patent_doc_number] => 20170253646 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-07 [patent_title] => 'Functional Peptide Analogs of PEDF' [patent_app_type] => utility [patent_app_number] => 15/477934 [patent_app_country] => US [patent_app_date] => 2017-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 34283 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15477934 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/477934
Functional Peptide Analogs of PEDF Apr 2, 2017 Abandoned
Array ( [id] => 16570644 [patent_doc_number] => 20210009650 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => MODIFIED FIBROBLAST GROWTH FACTORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/089698 [patent_app_country] => US [patent_app_date] => 2017-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46915 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16089698 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/089698
MODIFIED FIBROBLAST GROWTH FACTORS AND USES THEREOF Mar 23, 2017 Abandoned
Array ( [id] => 11728044 [patent_doc_number] => 20170189486 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-06 [patent_title] => 'MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/460917 [patent_app_country] => US [patent_app_date] => 2017-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 81 [patent_figures_cnt] => 81 [patent_no_of_words] => 89672 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15460917 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/460917
Therapeutic uses of modified FGF-21 polypeptides Mar 15, 2017 Issued
Array ( [id] => 11850282 [patent_doc_number] => 20170224774 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-10 [patent_title] => 'METHOD FOR USING SUPPLEMENTAL VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) OR ANALOG TO PREVENT OXYGEN INDUCED ARREST OF VESSEL GROWTH AND DISEASE SEQUELA OF PREMATURE INFANT BIRTH' [patent_app_type] => utility [patent_app_number] => 15/425872 [patent_app_country] => US [patent_app_date] => 2017-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1914 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15425872 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/425872
METHOD FOR USING SUPPLEMENTAL VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) OR ANALOG TO PREVENT OXYGEN INDUCED ARREST OF VESSEL GROWTH AND DISEASE SEQUELA OF PREMATURE INFANT BIRTH Feb 5, 2017 Abandoned
Array ( [id] => 11850283 [patent_doc_number] => 20170224775 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-10 [patent_title] => 'Lv PEPTIDE, ANTI-Lv ANTIBODY AND METHODS THEREOF' [patent_app_type] => utility [patent_app_number] => 15/424816 [patent_app_country] => US [patent_app_date] => 2017-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 8288 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15424816 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/424816
Lv PEPTIDE, ANTI-Lv ANTIBODY AND METHODS THEREOF Feb 3, 2017 Abandoned
Array ( [id] => 11618221 [patent_doc_number] => 20170128408 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-11 [patent_title] => 'NANOPARTICLE COMPLEXES OF PACLITAXEL, ALEMTUZUMAB, AND ALBUMIN' [patent_app_type] => utility [patent_app_number] => 15/414536 [patent_app_country] => US [patent_app_date] => 2017-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 57 [patent_figures_cnt] => 57 [patent_no_of_words] => 20275 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15414536 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/414536
Methods for treating CD52-expressing cancers using compositions comprising nanoparticle complexes of paclitaxel, alemtuzumab, and albumin Jan 23, 2017 Issued
Array ( [id] => 15099701 [patent_doc_number] => 10471145 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-12 [patent_title] => Methods for treating cancer using nanoparticle complexes of paclitaxel, rituximab, and albumin [patent_app_type] => utility [patent_app_number] => 15/414533 [patent_app_country] => US [patent_app_date] => 2017-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 58 [patent_figures_cnt] => 92 [patent_no_of_words] => 19244 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15414533 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/414533
Methods for treating cancer using nanoparticle complexes of paclitaxel, rituximab, and albumin Jan 23, 2017 Issued
Array ( [id] => 11618400 [patent_doc_number] => 20170128587 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-11 [patent_title] => 'NANOPARTICLE COMPLEXES OF ANTI-CD20 ANTIBODIES, ALBUMIN AND PACLITAXEL' [patent_app_type] => utility [patent_app_number] => 15/414526 [patent_app_country] => US [patent_app_date] => 2017-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 56 [patent_no_of_words] => 20273 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15414526 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/414526
Nanoparticle complexes of rituximab, albumin and pacltaxel Jan 23, 2017 Issued
Array ( [id] => 11618399 [patent_doc_number] => 20170128586 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-11 [patent_title] => 'CANCER TREATMENTS' [patent_app_type] => utility [patent_app_number] => 15/412596 [patent_app_country] => US [patent_app_date] => 2017-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 57 [patent_figures_cnt] => 57 [patent_no_of_words] => 20276 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15412596 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/412596
Nanoparticle complexes of paclitaxel, cetuximab, and albumin, and methods of making the same Jan 22, 2017 Issued
Array ( [id] => 11618397 [patent_doc_number] => 20170128584 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-11 [patent_title] => 'CANCER TREATMENTS' [patent_app_type] => utility [patent_app_number] => 15/412564 [patent_app_country] => US [patent_app_date] => 2017-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 56 [patent_no_of_words] => 20275 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15412564 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/412564
Nanoparticle complexes of paclitaxel, cetuximab, and albumin Jan 22, 2017 Issued
Array ( [id] => 11742758 [patent_doc_number] => 20170196831 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-13 [patent_title] => 'NANOPARTICLE COMPLEXES OF PACLITAXEL, ANTI-HER2 ANTIBODY, AND ALBUMIN' [patent_app_type] => utility [patent_app_number] => 15/412536 [patent_app_country] => US [patent_app_date] => 2017-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 56 [patent_no_of_words] => 20692 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15412536 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/412536
Nanoparticle complexes of paclitaxel, trastuzumab, and albumin Jan 22, 2017 Issued
Array ( [id] => 11618395 [patent_doc_number] => 20170128583 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-11 [patent_title] => 'NANOPARTICLE COMPLEXES OF PACLITAXEL, TRASTUZUMAB, AND ALBUMIN' [patent_app_type] => utility [patent_app_number] => 15/412554 [patent_app_country] => US [patent_app_date] => 2017-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 57 [patent_figures_cnt] => 57 [patent_no_of_words] => 20277 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15412554 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/412554
Methods of treating cancer with antibody-albumin nanoparticle complexes comprising albumin, trastuzumab, and paclitaxel Jan 22, 2017 Issued
Array ( [id] => 11742761 [patent_doc_number] => 20170196833 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-13 [patent_title] => 'NANOPARTICLE COMPLEXES OF PACLITAXEL, BEVACIZUMAB, AND ALBUMIN' [patent_app_type] => utility [patent_app_number] => 15/413257 [patent_app_country] => US [patent_app_date] => 2017-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 56 [patent_no_of_words] => 20688 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15413257 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/413257
Antibody-albumin nanoparticle complexes comprising albumin, bevacizumab, and paclitaxel, and methods of making and using the same Jan 22, 2017 Issued
Array ( [id] => 15191359 [patent_doc_number] => 10493150 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-03 [patent_title] => Nanoparticle complexes of paclitaxel, alemtuzumab, and albumin [patent_app_type] => utility [patent_app_number] => 15/412610 [patent_app_country] => US [patent_app_date] => 2017-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 58 [patent_figures_cnt] => 92 [patent_no_of_words] => 19241 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15412610 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/412610
Nanoparticle complexes of paclitaxel, alemtuzumab, and albumin Jan 22, 2017 Issued
Array ( [id] => 11618398 [patent_doc_number] => 20170128585 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-11 [patent_title] => 'CANCER TREATMENTS' [patent_app_type] => utility [patent_app_number] => 15/412581 [patent_app_country] => US [patent_app_date] => 2017-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 57 [patent_figures_cnt] => 57 [patent_no_of_words] => 20274 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15412581 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/412581
Methods for treating cancer using nanoparticle complexes of paclitaxel, cetuximab, and albumin Jan 22, 2017 Issued
Array ( [id] => 11963581 [patent_doc_number] => 20170267735 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-21 [patent_title] => 'VASCULAR ENDOTHELIAL GROWTH FACTOR ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 15/411112 [patent_app_country] => US [patent_app_date] => 2017-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 27774 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15411112 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/411112
Vascular endothelial growth factor antagonists and methods of making Jan 19, 2017 Issued
Array ( [id] => 13795837 [patent_doc_number] => 20190011457 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-10 [patent_title] => BIOMARKERS FOR DIAGNOSING KELOID SKIN OR KELOID SCAR, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/070121 [patent_app_country] => US [patent_app_date] => 2017-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7081 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 594 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16070121 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/070121
BIOMARKERS FOR DIAGNOSING KELOID SKIN OR KELOID SCAR, AND USE THEREOF Jan 12, 2017 Abandoned
Menu